ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a leader in development of innovative therapeutics for life-threatening and life-debilitating diseases, announced today that it has received FDA approval to begin Phase II trials for Archexin™, the Company’s leading cancer compound, for the treatment of pancreatic cancer. This will be a multi-center trial with preliminary data in humans expected in 2010.
